Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GNC Mines Gold Card Data To Engage, Retain Customers

This article was originally published in The Tan Sheet

Executive Summary

Each GNC “mySource” brochure “is based on the things that the customers told us mattered most,” says CEO Mike Archbold. Gold Card data are “an enormously rich asset in terms of understanding who the customers are,” says consultant Peter Miles-Prouten.

You may also be interested in...

GNC's Turnaround Moves Ahead On Email Addresses, Amazon Launch

Email addresses for all customers joining its loyalty programs, reaching nearly 5.5m since the 2016 fourth quarter, and adding an Amazon storefront to its e-commerce business are key reasons behind the firm's confidence in its turnaround.

GNC Makes Change At Helm As Revenue Decline Continues

The firm reports lower second-quarter revenues across its retail operations, domestically and internationally, and for company and franchise stores, and a 2.4% drop in consolidated revenues to $673.2m. Same-store sales, including its website, were off 3.7% and net income slipped 5% to $64m.

Proposed OTC Switch Rule Anticipates Digital World

FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts